114P Targeting the EGF-receptor and CD38 in solid and haematological malignancies with nanobody-based heavy chain antibodies and AAV vectors

ConclusionNanobody-based hcAbs and nanobody-displaying AAV hold promise as novel tools to target solid and hematological tumors.Legal entity responsible for the studyFriedrich Koch-Nolte.FundingDFG (German Research Foundation) and SFB (Collaborative Research Centres).DisclosureThe author has declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research